CSF Biomarker May Support Lewy Body Diagnosis - Top-Institutions - MDSpire

CSF Biomarker May Support Lewy Body Diagnosis

A multicohort analysis suggests cerebrospinal fluid DOPA decarboxylase may help distinguish dementia with Lewy bodies and Parkinson’s disease from Alzheimer’s disease and controls

  • By

  • Henry Thomas

  • April 3, 2026

  • 2 min

Share

Top Institutions in Neurology

Brief introduction explaining scope and methodology.

  • #1

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Neurology
    • Neurodegenerative Diseases
    • Biomarker Research

  • #2

    Johns Hopkins University
    Johns Hopkins University

    Baltimore, MD

    Key Differentiators

    • Neurology
    • Neurodegeneration
    • Biomarker Development

  • #3

    University of California, San Francisco (UCSF)
    University of California, San Francisco (UCSF)

    San Francisco, CA

    Key Differentiators

    • Neurology
    • Movement Disorders
    • Neurodegenerative Biomarkers

  • #4

    Washington University in St. Louis
    Washington University in St. Louis

    St. Louis, MO

    Key Differentiators

    • Neurology
    • Neurodegenerative Disease Research
    • Biomarker Discovery

  • #5

    University of Pennsylvania
    University of Pennsylvania

    Philadelphia, PA

    Key Differentiators

    • Neurology
    • Neurodegenerative Disorders
    • Biomarker Research

Original Source(s)

CSF Biomarker May Support Lewy Body Diagnosis

  • by Henry Thomas

  • April 3, 2026

Related Content